Drugs / BNT142
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05262530 | Mar 2022 → Dec 2025 | cancer | BioNTech SE | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-05-27 | BioNTech SE | Results BioNTech to Present Progress Across Diversified Oncology Pipeline at the 2025 ASCO Annual Meeting biontech.com ↗
Preliminary data indicated a manageable safety profile and early signs of clinical activity, supporting scientific proof-of-concept and underscoring the potential of mRNA-encoded bispecific antibodies. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-05-27 | BioNTech SE | BioNTech to Present Progress Across Diversified Oncology Pipeline at the 2025 ASCO Annual Meeting biontech.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BNT142 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05262530 ↗ |
| Route | Intravenous | “Intravenous bolus/infusion” NCT05262530 ↗ |
| Target | CLDN6 | “a T cell-engaging bispecific antibody that monovalently binds the T cell marker CD3 and bivalently binds claudin 6 (CLDN6), an oncofetal antigen” PMID 38776391 ↗ May 2024 |